As part of the administration’s commitment toward lowering drug prices, Centers for Medicare & Medicaid Services (CMS) published a proposed rule supporting the following: 

• Flexibility to enter into innovative value-based purchasing arrangements (VBPs) with drug manufacturers for new expensive therapies  
• Provide manufacturers with regulatory flexibility to enter into VBPs with payers, including Medicaid 
• Create minimum standards in state Medicaid Drug Utilization Review (DUR) programs designed to reduce opioid-related fraud, misuse and abuse

Watch this on-demand webinar presented by Melonie Warfel and Jesse Mendelsohn from Model N, John O’Brien, former Senior Advisor to the Secretary of Health and Human Services, and Brian McCartney, Senior Director Market Access Policy & Government Reporting from AstraZeneca to gain insights on the latest effort by the administration to move toward paying on the basis of value instead of volume while still ensuring that Medicaid continues to get the best price.